Pharmaceutical Technology28d
HM-001 by HOIST for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
HM-001 is under clinical development by HOIST and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer). According to GlobalData, Phase II drugs for Non ...
Pharmaceutical Technology1mon
NP-001 by Neuvivo for Primary Progressive Multiple Sclerosis (PPMS): Likelihood of Approval
The drug candidate is administered as an intravenous infusion. NP-001 is a purified form of sodium chlorite which aims at slowing or even stopping the progression of ALS. NP-001 targets immune system ...
Frontiers2y
An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis
Attempts to design small molecule therapies directed to this cytokine have not led to approved products yet. Here we report the discovery and development of a potent small molecule inhibitor of TNF ...